Enhancing the Immunogenicity of Vaccinia Virus

Щелкунов, С. Н.; Yakubitskiy, S. N.; Сергеев, А. А.; Starostina, Ekaterina; Titova, Ksenia A.; Pyankov, Stepan A.; Shchelkunova, Galina A.; Borgoyakova, M. B.; Zadorozhny, Alexey M.; Орлова, Л. А.; Kisakov, Denis N.; Karpenko, Larisa I.

doi:10.3390/v14071453

Cited by 9 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BALB/c mice aged 6–7 weeks were immunized with the LIVP and LIVPΔati VACV strains by making an intradermal (i.d.) injection into the dorsal side of the tail (~ 1 cm from the tail base), according to the procedure described earlier [ 19 ] using a virus dose of 105 pfu/20 μL/mouse. The mice that had received saline were used as negative controls.…”

Section: Methodsmentioning

confidence: 99%

“…Мышей линии BALB/c в возрасте 6-7 недель иммунизировали штаммами LIVP и LIVP∆ati VACV: внутрикожная (в/к) инъекция в дорсальную сторону хвоста (около 1 см от основания) как описано ранее [19], используя дозу вируса 10 5 БОЕ/20 мкл/мышь. В качестве отрицательного контроля использовали мышей, которым вводили физиологический раствор.…”

Section: иммунизация мышей и взятие образцов на анализыunclassified

See 1 more Smart Citation

Effect of the <i>ati</i> Gene Deletion on the Pathogenicity and Immunogenicity of the Vaccinia Virus

Yakubitskiy,

Sergeev,

Titova

et al. 2023

Acta Naturae

Self Cite

View full text Add to dashboard Cite

Among the nonvirion proteins of the vaccinia virus (VACV), a 94-kDa long protein is most abundantly present; the protein is a truncated form of the 150-kDa A-type inclusion (ATI) protein of the cowpox virus encoded by the ati gene. This VACV protein does not form intracellular ATIs, being as it is a major immunogen upon infection/immunization of humans or animals with the VACV. Antibodies specific to this protein are not virus-neutralizing. The present study focused on the effect of the production of this nonstructural major immunogenic VACV protein on the manifestation of pathogenicity and immunogenicity of the virus in the BALB/c mouse model of infection. In order to introduce a targeted deletion into the VACV LIVP genome, the recombinant integration/deletion plasmid p∆ati was constructed and further used to generate the recombinant virus LIVP∆ati. The pathogenicity of the VACV LIVP and LIVP∆ati strains was studied in 3-week-old mice. The mice were intranasally infected with the viruses at a dose of 107 pfu; 50% of the animals infected with the parent LIVP strain died, while infection with the LIVP∆ati strain led to the death of only 20% of the mice. Intradermal vaccination of mice aged 67 weeks with the LIVP∆ati virus statistically significantly increased the production of VACV-specific IgG, compared to that after intradermal vaccination with VACV LIVP. Meanwhile, no differences were noted in the cell-mediated immune response to the vaccination of mice with VACV LIVP or LIVP∆ati, which was assessed by ELISpot according to the number of splenocytes producing IFN- in response to stimulation with virus-specific peptides. Intranasal infection of mice with lethal doses of the cowpox virus or the ectromelia virus on day 60 post-immunization with the studied VACV variants demonstrated that the mutant LIVP∆ati elicits a stronger protective response compared to the parent LIVP.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: иммунизация мышей и взятие образцов на анализыunclassified

Effect of the <i>ati</i> Gene Deletion on the Pathogenicity and Immunogenicity of the Vaccinia Virus

Yakubitskiy,

Sergeev,

Titova

et al. 2023

Acta Naturae

Self Cite

View full text Add to dashboard Cite

show abstract

“…Для каждого образца анализ проводили в повторах. Для стимуляции клеток использовали смесь VACV-специфичных иммунодоминантных для мышей линии BALB/c пептидов SPYAAGYDL, SPGAAGYDL, VGPSNSPTF, KYGRLFNEI, GFIRSLQTI, KYMWCYSQV [18]. Смесь пептидов (100 мкл на ячейку) добавляли в концентрации 20 мкг/мл каждого пептида.…”

Section: определение количества Ifn-γ-продуцирующих клеток с использо...unclassified

Comparison of the Effectiveness of Transepidemal and Intradermal Immunization of Mice with the Vacinia Virus

et al. 2023

View full text Add to dashboard Cite

The spread of the monkeypox virus infection among humans in many countries outside of Africa, which started in 2022, is now drawing the attention of the medical and scientific communities to the fact that immunization against this infection is sorely needed. According to current guidelines, immunization of people with the first-generation smallpox vaccine based on the vaccinia virus (VACV) LIVP strain, which is licensed in Russia, should be performed via transepidermal inoculation (skin scarification, s.s.). However, the long past experience of using this vaccination technique suggests that it does not ensure virus inoculation into patients skin with enough reliability. The procedure of intradermal (i.d.) injection of a vaccine can be an alternative to s.s. inoculation. The effectiveness of i.d. vaccination can depend on the virus injection site on the body. Therefore, the aim of this study was to compare the development of the humoral and cellular immune responses in BALB/c mice immunized with the LIVP VACV strain, which was administered either by s.s. inoculation or i.d. injection into the same tail region of the animal. A virus dose of 105 pfu was used in both cases. ELISA of serum samples revealed no significant difference in the dynamics and level of production of VACV-specific IgM and IgG after i.d. or s.s. vaccination. A ELISpot analysis of splenocytes from the vaccinated mice showed that i.d. administration of VACV LIVP to mice induces a significantly greater T-cell immune response compared to s.s. inoculation. In order to assess the protective potency, on day 45 post immunization, mice were intranasally infected with lethal doses of either the cowpox virus (CPXV) or the ectromelia virus (ECTV), which is evolutionarily distant from the VACV and CPXV. Both vaccination techniques ensured complete protection of mice against infection with the CPXV. However, when mice were infected with a highly virulent strain of ECTV, 50% survived in the i.d. immunized group, whereas only 17% survived in the s.s. immunized group. It appears, therefore, that i.d. injection of the VACV can elicit a more potent protective immunity against orthopoxviruses compared to the conventional s.s. technique.

show abstract

“…The underpinning reasons of efficiency of VACV vaccines for both MPXV and variola virus is due to the high similarity in the most of the proteins of these viruses. [103,104] Historically, development of VACV vaccines consists of four generations. In the first generation, the live animals were utilized to growth the different vaccines.…”

Section: Bio-nano For Mpxv Vaccine Developmentmentioning

confidence: 99%

Addressing the Silent Spread of Monkeypox Disease with Advanced Analytical Tools

Bhalla

Payam

2022

Small

View full text Add to dashboard Cite

show abstract

Enhancing the Immunogenicity of Vaccinia Virus

Cited by 9 publications

References 32 publications

Effect of the <i>ati</i> Gene Deletion on the Pathogenicity and Immunogenicity of the Vaccinia Virus

Effect of the <i>ati</i> Gene Deletion on the Pathogenicity and Immunogenicity of the Vaccinia Virus

Comparison of the Effectiveness of Transepidemal and Intradermal Immunization of Mice with the Vacinia Virus

Addressing the Silent Spread of Monkeypox Disease with Advanced Analytical Tools

Contact Info

Product

Resources

About